All You Need to Know about BRS

هشتمين كنگره بين المللي قلب و عروق رضوي

6 الي 8 مرداد 1395، مشهد - ايران

Presentation Type: Speech

Second and third generation drug-eluting stents (DES) has demonstrated excellent clinical outcomes in patients with coronary artery disease. However, a continued risk of clinical events even several years after the procedure is reported. Stent platform or polymer-associated inflammation may play a role. Bioresorbable scaffold (BRS) is known to disappear 2 to 3 years after the implantation, which may result in the more favorable very long-term clinical outcomes compared with metallic stents. The initial clinical experiences of BRS in relatively simple lesion subsets were comparable to DESs. BRS, however, is limited by the disadvantageous mechanical characteristics such as thick strut and the risk of fracture by overdilation. There is concern that BRS is less optimal for complex lesion subsets such as bifurcation lesions, calcified tortuous lesions, or diffuse long lesions. Besides the implantation technique of BRS is totally different from DES. Aims of this lecture is to summarize clinical trials and real world registry.